Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence.
PAD inhibition should be framed as a mechanistically distinct, still-preclinical adjunct to the KDIGO 2024 standard of care, with its renal potential depending on isoform-resolved human data and pharmacokinetic characterization in chronic kidney disease.